It's a fair question, but I'm going to start by basically dodging it and say that we can't know all the things that a plugged-in front office can know, such as who might be available given the right price. Among the candidates we think we knew about, we saw that Luis Castillo got traded just days earlier, for a much steeper and more painful price, and the Mariners subsequently signed him to an extension slightly larger than what we (recently) have given Pablo Lopez. With Royce Lewis injured by then and Brooks Lee not yet available for trade, I don't know if we even had what the Reds were demanding, if we piled 10 "good" prospects into our offer. Also acquiring Castillo might mean not going after Pablo Lopez this past off-season if the plan were to extend Lopez too. Wheels within wheels, when deciding.
So... I'm back to "but not Mahle." My own data-free analysis was that Mahle was at the time too high a medical risk, just based on his recent health record at the time; he had a solid 2021 but was on the IL in '22 for a shoulder problem, and shoulders scare me as much or more than elbows (though ironically it looks like the elbow is what got Mahle this time). I trust that teams have better analytics on pitcher health than I do (more data, more time to experiment with "models" of what contributes to good risks and what doesn't), and yet I maintain they missed something that seemed obvious to me. So, if it were me as GM, I'd have gone back to my underlings and told them, go through the list of candidates and get me someone else.
And if they came back again and said there was no one, Mahle or nobody, then I guess I don't trade those prospect chips after all. I hate that answer, because we were in first place at the time (and had been sinking for two months or so), and you don't want to punt. But they say that sometimes the best trades are the ones you don't make.
And then that contradicts the success they've had with other trades. Not to mention that every pitcher comes with health risks. Every. Single. One.
But at heart, I believe that there are analytics that no one publishes for public consumption about this whole topic, and that some teams have a better handle on pitching risk than others do, and when we traded for Paddack and then for Mahle, we were seeing the difference. I'll always link the trades for Paddack and Mahle together, as a calculation that the way to win a World Series is by having high-end talent, and the mid-market teams have to assume more health risk to get those arms and then hope. I don't especially like it.